

Table 12.12
Adjusted Patient Survival, Deceased Donor Lung Transplants
Survival at 3 Months, 1 Year, 5 Years, and 10 Years

	3 Months			1 Year			5 Years			10 Years		
	(Tx 2006 - 2007)			(Tx 2006 - 2007)			(Tx 2002 - 2007)			(Tx 1997 - 2007)		
	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.
Total												
All	2,718	92.6%	0.5%	2,718	84.0%	0.7%	7,199	53.5%	0.8%	11,661	27.0%	0.8%
Age at Tx												
<1 Year	8	88.9%	10.4%	8	82.5%	14.0%	22	52.1%	14.1%	43	38.8%	9.2%
1-5 Years	11	86.0%	9.4%	11	86.0%	9.4%	25	57.6%	13.9%	50	41.2%	9.1%
6-11 Years	19	100.0%	0.0%	19	97.0%	3.4%	52	66.2%	8.5%	99	39.0%	8.7%
12-17 Years	62	97.4%	1.8%	62	94.8%	2.6%	168	38.2%	6.2%	267	18.8%	4.5%
18-34 Years	325	95.4%	1.2%	325	89.2%	2.1%	882	52.3%	3.0%	1,473	34.8%	2.3%
35-49 Years	414	93.4%	1.2%	414	90.4%	1.4%	1,272	60.2%	1.8%	2,351	37.0%	1.6%
50-64 Years	1,508	91.6%	0.8%	1,508	81.1%	1.2%	4,075	53.2%	1.2%	6,499	22.7%	1.2%
65+ Years	371	90.3%	1.6%	371	76.8%	2.3%	703	48.0%	3.2%	879	14.0%	3.3%
Recipient Ethnicity/Race												
White	2,297	92.8%	0.5%	2,297	84.0%	0.8%	6,194	53.2%	0.9%	10,185	27.1%	0.9%
African American	239	91.5%	1.9%	239	84.8%	2.6%	558	57.4%	2.9%	864	24.9%	3.1%
Hispanic/Latino	135	90.7%	2.4%	135	82.5%	3.2%	326	49.4%	4.2%	451	31.9%	3.8%
Asian	27	93.0%	4.7%	27	78.7%	7.6%	77	61.4%	6.9%	104	27.8%	9.4%
Other/Multi-race	20	100.0%	0.0%	20	94.2%	5.5%	42	58.8%	9.7%	55	34.5%	10.2%
Unknown	0	-	-	0	-	-	2	+	+	2	+	+
Recipient Gender												
Female	1,173	92.9%	0.8%	1,173	83.7%	1.1%	3,292	53.6%	1.2%	5,542	27.4%	1.2%
Male	1,545	92.4%	0.7%	1,545	84.2%	0.9%	3,907	53.4%	1.1%	6,119	26.7%	1.1%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

(+) = Values not determined due to insufficient follow-up. (-) = Values not determined since there were no transplants in the category.

Cohorts are transplants performed during the years listed at the top of the table.

Patient survival follows patients from first transplant of this type until death. Counts for patient and graft survival are different because a patient may have more than one transplant for a type of organ.

Center volume = Center's yearly transplants performed during the base period, based on lung and heart-lung transplants.

Multi-organ transplants are excluded.

Survival rates are adjusted to the characteristics of the 3 month and 1 year cohort. See Technical Notes for details.

Table 12.12 (Continued)
Adjusted Patient Survival, Deceased Donor Lung Transplants
Survival at 3 Months, 1 Year, 5 Years, and 10 Years

	3 Months			1 Year			5 Years			10 Years		
	(Tx 2006 - 2007)			(Tx 2006 - 2007)			(Tx 2002 - 2007)			(Tx 1997 - 2007)		
	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.
Total												
All	2,718	92.6%	0.5%	2,718	84.0%	0.7%	7,199	53.5%	0.8%	11,661	27.0%	0.8%
Primary Diagnosis												
Emphysema/COPD	837	94.7%	0.7%	837	87.3%	1.2%	2,515	55.1%	1.4%	4,422	24.3%	1.3%
Cystic Fibrosis	402	92.4%	1.8%	402	80.7%	3.0%	1,096	54.2%	2.5%	1,827	32.6%	2.0%
Idiopathic Pulmonary Fibrosis	854	91.8%	0.9%	854	82.2%	1.4%	1,941	50.9%	1.7%	2,642	26.0%	2.0%
Alpha-1-Antitrypsin Deficiency	86	94.4%	2.4%	86	88.8%	3.3%	337	61.0%	3.2%	710	27.4%	2.7%
Idiopathic Pulmonary Arterial Hypertension	54	86.0%	5.3%	54	83.7%	5.6%	208	55.8%	4.3%	405	33.4%	3.6%
Congenital Disease	1	+	+	1	+	+	26	51.1%	10.0%	90	34.5%	5.6%
Other	484	90.3%	1.4%	484	81.6%	1.8%	1,076	56.2%	2.2%	1,565	34.1%	2.3%
Lung Diagnosis Group												
Group A: Obstructive Lung Disease	1,048	92.5%	2.6%	1,048	82.5%	5.6%	3,209	43.9%	5.2%	5,698	18.6%	3.0%
Group B: Pulmonary Vascular Disease	91	92.0%	6.9%	91	86.7%	10.9%	281	44.0%	17.9%	519	27.6%	9.7%
Group C: Cystic Fibrosis or Immunodef. Disorders	398	89.5%	10.0%	398	75.6%	21.1%	1,074	56.9%	11.3%	1,778	35.0%	7.9%
Group D: Restrictive Lung Disease	1,123	94.2%	1.7%	1,123	87.6%	3.4%	2,479	61.5%	3.9%	3,364	34.0%	3.5%
Group E: Age Less Than 12	38	75.6%	16.1%	38	64.7%	19.9%	99	64.3%	7.8%	192	44.3%	6.5%
Other Diagnosis	20	95.0%	4.9%	20	95.0%	4.9%	57	69.5%	8.0%	110	28.3%	8.8%
Lung Allocation Score												
LAS 0	5	68.9%	22.9%	5	68.9%	22.9%	0	-	-	0	-	-
LAS 20 - 29	20	83.1%	8.4%	20	83.1%	8.4%	0	-	-	0	-	-
LAS 30 - 34	955	94.2%	0.8%	955	86.4%	1.3%	0	-	-	0	-	-
LAS 35 - 39	709	93.9%	0.9%	709	84.1%	1.4%	0	-	-	0	-	-
LAS 40 - 49	584	91.8%	1.1%	584	83.8%	1.6%	0	-	-	0	-	-
LAS 50 - 59	172	93.2%	1.8%	172	85.2%	2.7%	0	-	-	0	-	-
LAS 60+	273	86.2%	2.1%	273	74.5%	2.8%	0	-	-	0	-	-
Unknown	0	-	-	0	-	-	7,199	53.5%	0.8%	11,661	27.0%	0.8%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

(+) = Values not determined due to insufficient follow-up. (-) = Values not determined since there were no transplants in the category.

Cohorts are transplants performed during the years listed at the top of the table.

Patient survival follows patients from first transplant of this type until death. Counts for patient and graft survival are different because a patient may have more than one transplant for a type of organ.

Center volume = Center's yearly transplants performed during the base period, based on lung and heart-lung transplants.

Multi-organ transplants are excluded.

Survival rates are adjusted to the characteristics of the 3 month and 1 year cohort. See Technical Notes for details.

Table 12.12 (Continued)
Adjusted Patient Survival, Deceased Donor Lung Transplants
Survival at 3 Months, 1 Year, 5 Years, and 10 Years

	3 Months			1 Year			5 Years			10 Years		
	(Tx 2006 - 2007)			(Tx 2006 - 2007)			(Tx 2002 - 2007)			(Tx 1997 - 2007)		
	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.
Total												
All	2,718	92.6%	0.5%	2,718	84.0%	0.7%	7,199	53.5%	0.8%	11,661	27.0%	0.8%
Transplant Center State												
Alabama	60	90.9%	3.5%	60	81.5%	4.8%	166	43.9%	5.0%	324	21.8%	4.2%
Arizona	39	86.9%	5.4%	39	79.0%	6.5%	67	63.2%	7.7%	91	30.6%	11.0%
California	335	94.0%	1.2%	335	86.7%	1.8%	926	51.3%	2.4%	1,345	23.8%	2.5%
Colorado	60	95.3%	2.6%	60	88.8%	4.0%	198	48.7%	4.7%	333	25.0%	4.2%
Florida	215	94.5%	1.5%	215	90.1%	2.0%	479	60.8%	3.3%	618	31.0%	4.8%
Georgia	50	94.2%	3.2%	50	84.3%	5.0%	130	47.5%	6.8%	184	25.6%	5.6%
Iowa	5	+	+	5	+	+	5	+	+	5	+	+
Illinois	80	94.1%	2.6%	80	82.1%	4.2%	205	60.7%	4.8%	380	29.2%	4.4%
Indiana	61	84.2%	4.6%	61	71.3%	5.7%	225	46.5%	4.5%	334	14.2%	4.4%
Kentucky	46	98.0%	2.0%	46	83.5%	5.3%	123	38.9%	6.6%	218	8.8%	4.1%
Louisiana	0	-	-	0	-	-	58	49.0%	6.6%	150	16.7%	4.0%
Massachusetts	56	92.5%	3.6%	56	75.7%	5.9%	185	42.8%	5.0%	321	21.8%	4.2%
Maryland	69	93.6%	2.8%	69	83.1%	4.3%	160	45.5%	5.8%	281	35.6%	3.9%
Michigan	73	88.2%	3.7%	73	80.2%	4.6%	193	55.7%	5.1%	384	27.0%	3.9%
Minnesota	103	95.2%	2.1%	103	87.6%	3.2%	269	58.0%	4.6%	441	33.7%	3.9%
Missouri	131	93.4%	2.3%	131	85.1%	3.2%	384	64.8%	3.1%	737	38.9%	2.8%
North Carolina	130	93.5%	2.1%	130	82.4%	3.3%	400	53.3%	3.4%	721	26.3%	3.0%
Nebraska	0	-	-	0	-	-	0	-	-	14	18.9%	9.5%
New Jersey	0	-	-	0	-	-	0	-	-	3	0.0%	0.0%
New York	125	93.7%	2.1%	125	85.8%	3.1%	268	59.9%	4.7%	396	32.2%	4.6%
Ohio	146	92.8%	2.1%	146	86.2%	2.8%	404	53.4%	3.5%	618	23.9%	3.5%
Oklahoma	18	88.8%	7.2%	18	66.2%	10.9%	83	23.2%	6.0%	113	17.8%	4.8%
Oregon	0	-	-	0	-	-	0	-	-	8	20.6%	12.4%
Pennsylvania	365	90.7%	1.5%	365	79.3%	2.1%	794	57.6%	2.4%	1,234	29.9%	2.5%
South Carolina	0	-	-	0	-	-	0	-	-	1	0.0%	0.0%
Tennessee	39	79.2%	6.4%	39	62.8%	7.8%	117	44.1%	5.5%	210	28.2%	4.1%
Texas	208	91.5%	1.9%	208	85.9%	2.4%	549	48.1%	2.9%	883	23.4%	2.6%
Utah	16	93.9%	5.8%	16	93.9%	5.8%	48	60.0%	8.2%	91	29.2%	7.4%
Virginia	113	94.9%	2.0%	113	86.4%	3.2%	295	56.5%	4.1%	482	22.6%	3.8%
Washington	101	94.4%	2.2%	101	87.8%	3.2%	259	57.5%	4.4%	363	18.3%	6.7%
Wisconsin	74	93.5%	2.8%	74	88.1%	3.7%	209	68.0%	4.1%	378	35.8%	4.7%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

(+) = Values not determined due to insufficient follow-up. (-) = Values not determined since there were no transplants in the category.

Cohorts are transplants performed during the years listed at the top of the table.

Patient survival follows patients from first transplant of this type until death. Counts for patient and graft survival are different because a patient may have more than one transplant for a type of organ.

Center volume = Center's yearly transplants performed during the base period, based on lung and heart-lung transplants.

Multi-organ transplants are excluded.

Survival rates are adjusted to the characteristics of the 3 month and 1 year cohort. See Technical Notes for details.